Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention

Inclusion Criteria

• Signed informed consent
• Hematologic disorder requiring allogeneic hematopoietic cell transplantation
• Left ventricular ejection fraction (LVEF) >= 45% by multigated acquisition (MUGA) scan or echocardiogram
• Forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and diffusion capacity of the lung for carbon monoxide (DLCO) adjusted >= 50% of predicted values on pulmonary function tests
• Aspartate aminotransferase < 3 times upper limit of normal value
• Alanine aminotransferase < 3 times upper limit of normal value
• Creatinine clearance calculated >= 50 mL/min
• Karnofsky performance status score >= 60%
• Human leukocyte antigen (HLA) matched 8/8 (A, B, C, DRB1) related or unrelated donor

Exclusion Criteria

• Active infection not controlled with appropriate antimicrobial therapy
• Human immunodeficiency virus (HIV), hepatitis B (hepatitis B core antibody [HBcAb] positive but hepatitis B surface antigen [HBsAg] negative with undetectable viral load are eligible), or hepatitis C infection
• Sorror’s co-morbidity factors with total score >= 4 * Important modification to co-morbidity index calculation: DLCO adjusted will not be included in assessment of pulmonary risk, except those patients with DLCO adjusted < 50% who are excluded from the trial
• Anti-thymocyte globulin as part of the conditioning regimen
• Cyclophosphamide as part of the conditioning regimen or for GVHD prophylaxis
• Pregnancy
• Histone deacetylase (HDAC), deacetylase (DAC), heat shock protein (HSP)90 inhibitors or valproic acid for the treatment of cancer within 30 days; only Food and Drug Administration (FDA) approved drug are vorinostat and romidepsin the rest are considered investigational and are not allowed
• Patients who will need valproic acid for any medical condition during the study or within 5 days prior to first PANO treatment
• Impaired cardiac function or clinically significant cardiac diseases, including any one of the following: * Any history of ventricular fibrillation or torsade de pointes * Bradycardia defined as heart rate (HR) < 45 beats per minute (bpm); patients with pacemakers are eligible if HR >= 45 bpm * Screening electrocardiogram with a QT corrected for Fridericia's formula (QTcF) >= 480 msec * Right bundle branch block + left anterior hemiblock (bifascicular block) * Patients with myocardial infarction or unstable angina =< 12 months prior to starting study drug * Other clinically significant heart disease (e.g., Classification of Heart failure [CHF] New York Heart Association class III or IV, uncontrolled hypertension) as per discretion of principal investigator and/or treating physician * Patients using medications that have a relative risk of prolonging the QT interval or inducing torsade de pointes if treatment cannot be discontinued or switched to a different medication prior to starting study drug with the exception of drugs that are required for hematopoietic cell transplantation (HCT) patients